Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent updates for the first quarter end...
Shares of Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at $4.04, breaking its 52-week low. So far today approximately 2.4 million shares have been exchanged, as compared to an average 30-day volume of 910,000 shares. Assembly Biosciences Inc. (NASDAQ:ASMB) has potential upside of...
Assembly Biosciences Inc. (NASDAQ:ASMB) traded today at a new 52-week low of $4.11. So far today approximately 2.4 million shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. In the past 52 weeks, Assembly Biosciences Inc. share prices are bracketed...
Assembly Biosciences, Inc. (ASMB) Hepatitis B Program Update Conference Call February 25, 2021 5:00 PM ET Company Participants Lauren Glaser - Senior Vice President of Investor Relations and Corporate Affairs John McHutchison - President and Chief Executive Officer Bill Delaney - Chief Scient...
Assembly Biosciences (ASMB) and Arbutus Biopharma (ABUS) have initiated a Phase 2 clinical trial of Assembly Bio’s investigational capsid inhibitor, vebicorvir ((VBR)), in combination with Arbutus’ GalNAc delivered RNAi therapeutic candidate, AB-729, and standard-of-care nucleos...
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasd...
Assembly Biosciences (ASMB): FY GAAP EPS of -$1.75 misses by $0.19.Revenue of $79.1M (+395.6% Y/Y) misses by $2.91M.Press Release For further details see: Assembly Biosciences EPS misses by $0.19, misses on revenue
Assembly Biosciences (ASMB) announced that it is foregoing plans to initiate Phase 3 registrational studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy ((CST)) to concentrate its research and development efforts on finite and curative HBV therapies.The decision co...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the fourth quarte...
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - Extends cash runway into 2023 - Company to host conference call toda...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on track to initiate by mid-2024 ABI-5366 interim Phase 1a first-in-human data expected in Q3 20...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...